UK genomics report calls for strategic innovation
This article was originally published in Scrip
The UK's Human Genomics Strategy Group (HGSG), established as part of the UK government's response to the 2009 House of Lords Inquiry into genomic medicine, has made a series of recommendations that it believes will enable the healthcare system in the UK - and particularly the National Health Service (NHS) - to benefit from the mainstream adoption of genomic technology.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.